Intai Technology (4163) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 鐿鈦

Intai Technology (4163) reported revenue of NT$253.7 million for Oct 2026, +49.0% year on year and +6.5% from the previous month. Revenue for Jan–Oct 2026 was NT$2.34 billion (+16.9% year on year).

Year-on-year revenue growth: 7 months in a row. →

In Oct 2026, it ranked No. 37 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$176.9 million24/10Nov 2024 NT$214.4 millionDec 2024 NT$187.5 millionJan 2025 NT$182.9 millionFeb 2025 NT$178.8 million25/02Mar 2025 NT$250.5 millionApr 2025 NT$197.4 millionMay 2025 NT$204.1 millionJun 2025 NT$207.6 million25/06Jul 2025 NT$193.6 millionAug 2025 NT$210.3 millionSep 2025 NT$202 millionOct 2025 NT$170.2 million25/10Nov 2025 NT$202 millionDec 2025 NT$205.8 millionJan 2026 NT$253.5 millionFeb 2026 NT$150.6 million26/02Mar 2026 NT$218.7 millionApr 2026 NT$237.5 millionMay 2026 NT$220.6 millionJun 2026 NT$223.5 million26/06Jul 2026 NT$290.2 millionAug 2026 NT$248.9 millionSep 2026 NT$238.3 millionOct 2026 NT$253.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$253.7 million+49.0%+6.5%
Sep 2026NT$238.3 million+18.0%-4.3%
Aug 2026NT$248.9 million+18.4%-14.2%
Jul 2026NT$290.2 million+49.9%+29.8%
Jun 2026NT$223.5 million+7.7%+1.3%
May 2026NT$220.6 million+8.1%-7.1%
Apr 2026NT$237.5 million+20.3%+8.6%
Mar 2026NT$218.7 million-12.7%+45.2%
Feb 2026NT$150.6 million-15.7%-40.6%
Jan 2026NT$253.5 million+38.6%+23.1%
Dec 2025NT$205.8 million+9.8%+1.9%
Nov 2025NT$202 million-5.8%+18.7%
Oct 2025NT$170.2 million-3.8%-15.7%
Sep 2025NT$202 million+2.0%-4.0%
Aug 2025NT$210.3 million+14.4%+8.6%
Jul 2025NT$193.6 million-6.5%-6.7%
Jun 2025NT$207.6 million+30.7%+1.7%
May 2025NT$204.1 million-11.6%+3.4%
Apr 2025NT$197.4 million-8.4%-21.2%
Mar 2025NT$250.5 million+34.0%+40.1%
Feb 2025NT$178.8 million-2.1%-2.3%
Jan 2025NT$182.9 million-21.7%-2.5%
Dec 2024NT$187.5 million+12.4%-12.5%
Nov 2024NT$214.4 million+10.2%+21.2%
Oct 2024NT$176.9 million-20.6%-10.7%

Jan–Oct 2026 cumulative: NT$2.34 billion (+16.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Intai Technology vs PEC / Intai Technology vs Lotus Pharm / Intai Technology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16